Biotechnology Jobs

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, ctDNA, flow cytometry and multi-omic analyses to inform dose selection and go/no-go decisions.

IHC/IF · Liquid Biopsy · ctDNA +3

• London
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Oversees biomarker assay development, sample testing plans and data packages across platforms such as NGS, IHC, flow cytometry and ctDNA, working with internal and external partners.

IHC/IF · Liquid Biopsy · ctDNA +3

• Waltham, United States
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy, regulatory submissions and cross-functional matrix teams.

AI/ML

• Stevenage
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human, dose-escalation and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, benefit-risk, regulatory submissions and translational biomarker strategy across lung and head/neck cancer assets.

AI/ML

• Zug, Switzerland
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy with cross-functional and regulatory partners.

AI/ML

• London
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, translational and biomarker strategy, and regulatory submissions across a lung and head/neck cancer portfolio.

AI/ML

• Waltham, United States
• Hybrid
• US$204,000 – US$340,000 pa
• Director

Leads the design and execution of real-world evidence and health outcomes studies for oncology assets, managing timelines, budgets and quality of protocols, analyses and publications. Advises internal medical, market access and commercial teams and external experts on evidence strategy for HTA submissions, reimbursement and value-based pricing. Requires close collaboration across a matrix and deep knowledge of real-world data sources and payer needs.

• London
• Hybrid
• US$204,000 – US$340,000 pa
• Director

Leads the design and execution of real-world evidence and health outcomes studies across oncology assets, managing timelines, budgets and quality of protocols, analyses and publications. Advises internal medical, market access and commercial teams and external experts on evidence strategy for HTA submissions, reimbursement and value-based pricing, while building knowledge of real-world data sources and payer needs.

• Rockville Tower Oaks Blvd
• Hybrid
• US$204,000 – US$340,000 pa
• Director

Leads the design and delivery of real-world evidence and health outcomes studies across oncology assets, managing protocols, budgets, timelines and vendor deliverables. Partners with medical, market access, R&D and commercial teams plus external experts to shape evidence for HTA submissions, reimbursement and value-based pricing. Requires deep knowledge of RWD sources and payer evidence requirements.

• Durham Blackwell Street
• Hybrid
• US$204,000 – US$340,000 pa
• Director

Leads the design and delivery of real-world evidence and health outcomes studies for oncology assets, managing protocols, budgets, vendors and reporting from concept to publication. Advises medical, market access and commercial teams on payer and HTA evidence needs, and builds relationships with external experts and data partners.

• London
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development of oncology assets in genitourinary cancers, overseeing Phase 1-3 interventional trials from protocol design through final study report. Provides real-time medical monitoring, safety review with pharmacovigilance, and regulatory document authoring, while building relationships with key external experts. Serves as a core member of the Clinical Matrix Team and contributes to disease area strategy and business development diligence.

• Waltham, United States
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development of GU oncology assets, designing and executing Phase 1-3 interventional trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds relationships with key external experts and represents the company at advisory boards and medical meetings.

• Stevenage
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development of GU oncology assets, designing and executing Phase 1-3 interventional trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds external expert relationships and represents the company at advisory boards and medical meetings.

• Zug, Switzerland
• On-site
• US$284,250 – US$473,750 pa
• Director

Leads clinical development for GU oncology assets, designing and executing Phase 1-3 interventional trials and serving as a core member of the Clinical Matrix Team. Provides real-time medical monitoring, safety review with pharmacovigilance, and authors clinical study reports and regulatory responses. Builds external expert relationships and represents the company at advisory boards and medical meetings.

• London
• Hybrid · 2 days in office
• US$202,500 – US$371,250 pa
• Director · manages people

Leads clinical development strategy for hepatology assets within GSK's Respiratory, Immunology & Inflammation Research Unit, from target identification through proof-of-concept studies. Accountable for clinical matrix team leadership, protocol design, medical monitoring and regulatory interactions across all development phases. Hybrid role with at least two on-site days weekly.